CHCWM – Cancer & Hematology Centers of West Michigan

Merck MK7902-015 (LEAP015)

 

    • A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK 7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
    • PI: Dr. Chandana
    • Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

Principal Investigator: Dr. Sreenivasa Chandana